Skip to main content

Fiscal Wizard · Single-issue tearsheet

HAE / Jun 21, 2026 Run #7502

HAE

Haemonetics Corporation

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Composite verdict

C 49.3 / 100
Gated stand-aside 0 drivers · 4 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 19th of 141 in Medical Devices

rescore-sweep
Technical synthesisRegime: uptrend

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -66%
Asset value $17.52Earnings power value $7.24Price $74.17

Priced above its no-growth earnings power value ($7.24/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

49.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Free Cash Flow Yield 96
Margin of Safety 0
FCF Margin 77
OCF to Net Income 0
EBITDA Margin 76
Cash Conversion 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 43 signals shown.

Risk Gates

4 blocking 7 caution

4 guards active, 43 signals gated.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for HAE.